


0120

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/511,465

Filing Date

February 7, 2005

First Named Inventor

Matthew H.T. Bui

Group Art Unit

Unassigned

Examiner Name

Unassigned

Total Number of Pages in This Submission

12

Attorney Docket Number

306J-000220US

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment / Response
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☒ PTO-1449 Form
- ☒ Copies of cited references
- ☒ Copy of PCT Search Report
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):

receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Christopher C. Sappenfield, Reg. No. 45,073, Quine Intellectual Property Law Group P.C.

Signature

Christopher C. Sappenfield

Date

March 28, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO via fax no. 703-306-5995 or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name


Deborah Berwick

Signature

Deborah Berwick

Date

March 29, 2005



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents
PO Box 1450

Alexandria, VA 22313-1450, on March 29, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By Deborah Berwick
Deborah Berwick

Attorney Docket No. 306J-000220US
Client Ref. No. 2002-463-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Matthew H.T. Bui, et al.

Application No.: 10/511,465

Filed: February 7, 2005

For: METHODS OF RENAL CELL
CARCINOMA PROGNOSIS AND
TREATMENT SELECTION WITH
CARBONIC ANHYDRASE IX

Confirmation No.

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of International Search Report for corresponding International Application No. PCT/US2003/11561. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Christopher C. Sappenfield
Reg. No. 45,073

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

CCS:db

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/511,465
Filing Date	October 14, 2004
First Named Inventor	Matthew H.T. Bui
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	306J-000220US
Date Submitted	March 29, 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	2002-0137910	A1	Zavada et al.	09-26-2002	
	2	2003-0049828	A1	Zavada et al.	03-13-2003	
	3	2004-0259126	A1	Zavada et al.	12-23-2004	
	4	2005-0003425	A1	Zavada et al.	01-06-2005	
	5	2005-0031623	A1	Pastorek et al.	02-10-2005	
	6	3,766,162		Hoffmann-La Roche, Inc	10-16-1973	
	7	3,791,932		Schuurs et al.	02-12-1974	
	8	3,817,837		Rubenstein et al.	06-18-1974	
	9	4,233,402		Maggio et al.	11-11-1980	
	10	5,387,676		Zavada et al.	02-07-1995	
	11	5,955,075		Zavada et al.	09-21-1999	
	12	5,972,353		Zavada et al.	10-26-1999	
	13	5,981,711		Zavada et al.	11-09-1999	
	14	5,989,838		Zavada et al.	11-23-1999	
	15	6,004,535		Zavada et al.	12-21-1999	
	16	6,027,887		Zavada et al.	02-22-2000	
	17	6,051,226		Zavada et al.	04-18-2000	
	18	6,069,242		Zavada et al.	05-30-2000	
	19	6,093,548		Zavada et al.	07-25-2000	
	20	6,204,370	B1	Zavada et al.	03-20-2001	
	21	6,297,041	B1	Zavada et al.	10-02-2001	
	22	6,297,051	B1	Zavada et al.	10-02-2001	
	23	6,770,438	B2	Zavada et al.	08-03-2004	
	24	6,774,117	B1	Zavada et al.	08-10-2004	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/511,465
Filing Date	October 14, 2004
First Named Inventor	Matthew H.T. Bui
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	306J-000220US
Date Submitted	March 29, 2005

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	25	WO	93/18152	A1	CIBA Corning Diagnostics Corp.	09-16-1993		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	26	BRETHERAU ET AL. (1995) "Prognostic value of nuclear grade of renal cell carcinoma." <i>Cancer</i> (Phila.) 76(12): 2543-2549.	
	27	BREWER ET AL. (1996) "A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN," <i>Gynecologic Oncology</i> 63: 337-344. (Article No. 0333)	
	28	BUI ET AL. (2001) "Prognostic factors and molecular markers for renal cell carcinoma." <i>Expert Review of Anticancer Therapy</i> , 1(4): 565-575.	
	29	BUI ET AL. (2003) "Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy." <i>Clinical Cancer Research</i> , 9:802-811.	
	30	DALBADIE-MCFARLAND ET AL. (1982) "Oligonucleotide-Directed Mutagenesis as a General and Powerful Method for Studies of Protein Function" <i>Proceeding of the National Academy of Sciences USA</i> , 79: 6409-6413.	
	31	DER AND STANBRIDGE (1981) "A tumor-specific membrane phosphoprotein marker in human cell hybrids." <i>Cell</i> 26: 429-438.	
	32	DIVGI ET AL. (1998) "Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma," <i>Clinical Cancer Research</i> , 4: 2729-2739.	
	33	ELSON ET AL. (1988) "Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma." <i>Cancer Research</i> , 48: 7310-7313.	
	34	FIGLIN (1999) "Renal cell carcinoma: management of advanced disease." <i>The Journal of Urology</i> , 161:381-386.	
	35	FLANIGAN ET AL. (2001) "Nephrectomy followed by interferon α -2b compared with interferon α -2b alone for metastatic renal-cell cancer." <i>New England Journal of Medicine</i> , 345(23): 1655-1659.	
	36	FUHRMAN ET AL. (1982) "Prognostic significance of morphologic parameters in renal cell carcinoma." <i>The American Journal of Surgical Pathology</i> , 6(7): 655-663.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/511,465
Filing Date	October 14, 2004
First Named Inventor	Matthew H.T. Bui
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	306J-000220US
Date Submitted	March 29, 2005

- | | |
|----|---|
| 37 | GALFRE AND MILSTEIN (1981) "Preparation of Monoclonal Antibodies: Strategies and Procedures." <i>Methods in Enzymology</i> , 73: 1-46. |
| 38 | GIATROMANOLAKI ET AL. (2001) "Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer." <i>Cancer Research</i> , 61:7992-7998. |
| 39 | GLENNIE AND STEVENSON (1982) "Univalent antibodies kill tumour cells <i>in vitro</i> and <i>in vivo</i> ." <i>Nature</i> 295: 712-714. |
| 40 | GORMAN ET AL. (1991) "Reshaping a Therapeutic CD4 Antibody." <i>Proceeding of the National Academy of Sciences USA</i> , 88:4181-4185. |
| 41 | IVANOV ET AL. (1998) "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes," <i>Proceeding of the National Academy of Sciences USA</i> , 95:12596-12601. |
| 42 | IVANOV ET AL. (2001) "Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer." <i>American Journal of Pathology</i> , 158(3):905-919. |
| 43 | JEMAL ET AL. (2002) "Cancer Statistics, 2002" <i>CA-Cancer J. Clin.</i> , 52(1):23-47. |
| 44 | KAPLAN AND MEIER (1958) "Nonparametric estimation from incomplete observations." <i>American Statistical Association Journal</i> , 53: 457-481. |
| 45 | KONONEN ET AL. (1998) "Tissue microarrays for high-throughput molecular profiling of tumor specimens." <i>Nature Medicine</i> , 4(7): 844-847. |
| 46 | LIAO ET AL. (1994) "Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas." <i>American Journal of Pathology</i> , 145(3): 598-609. |
| 47 | LIAO ET AL. (1997) "Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney." <i>Cancer Research</i> , 57: 2827-2831. |
| 48 | LONCASTER ET AL. (2001) "Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix." <i>Cancer Research</i> , 61:6394-6399. |
| 49 | KOHLER AND MILSTEIN (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity." <i>Nature</i> 256: 495-497. |
| 50 | MOTZER ET AL. (1999) "Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma." <i>Journal of Clinical Oncology</i> , 17(8): 2530-2540. |
| 51 | MURAKAMI ET AL. (1999) "MN/CA9 gene expression as a potential biomarker in renal cell carcinoma." <i>BJU International</i> , 83: 743-747. |
| 52 | OLIVE ET AL. (2001) "Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer," <i>Cancer Research</i> , 61:8924-8929. |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/511,465
Filing Date	October 14, 2004
First Named Inventor	Matthew H.T. Bui
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	306J-000220US
Date Submitted	March 29, 2005

- | | |
|----|---|
| 53 | OLSSON AND KAPLAN (1980) "Human-Hunam hybridomas producing monoclonal antibodies of predefined antigenic specificity." <i>Proceeding of the National Academy of Sciences USA</i> , 77(9): 5429-5431. |
| 54 | OOSTERWIJK ET AL. (1986) "Immunohistochemical analysis of monoclonal antibodies to renal antigens." <i>American Journal of Pathology</i> 123(2):301-309 |
| 55 | OOSTERWIJK ET AL. (1986) "Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney." <i>International Journal of Cancer</i> , 38: 489-494. |
| 56 | OOSTERWIJK ET AL. (1996) "Molecular characterization of the renal cell carcinoma-associated antigen G250," <i>Proceedings of the National Association for Cancer Research</i> , 37: #3147. |
| 57 | PANTUCK ET AL. (2001) "The changing natural history of renal cell carcinoma." <i>The Journal of Urology</i> , 166:1611-1623. |
| 58 | PARKKILA ET AL. (2000) "Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro." <i>Proceeding of the National Academy of Sciences USA</i> , 97(5):2220-2224. |
| 59 | PASTOREK ET AL. (1994) "Cloning and characterization of MN, a human tumor associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment." <i>Oncogene</i> 9: 2877-2888. |
| 60 | PASTOREKOVÁ ET AL. (1992) "A Novel Quasi-viral Agent, MaTu, Is a Two-Component system." <i>VIROLOGY</i> 187 :620-626. |
| 61 | RAK ET AL. (2002) "What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?" <i>Cancer Research</i> , 62:1931-1934. |
| 62 | ROILA ET AL. (1991) "Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales." <i>Annals of Oncology</i> 2: 437-439. |
| 63 | SAARNIO ET AL. (1998) "Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase. MN/CA IX, with potential value as a marker of cell proliferation." <i>American Journal of Pathology</i> , 153(1):279-285. |
| 64 | SCHLOM ET AL. (1980) "Generation of human monoclonal antibodies reactive with human mammary carcinoma cells." <i>Proceeding of the National Academy of Sciences USA</i> , 77(11):6841-6845. |
| 65 | SHEARMAN ET AL. (1991) "Construction, expression, and biologic activity of murine/human chimeric antibodies with specificity for the human alpha/beta T cell receptor." <i>The Journal of Immunology</i> , 146(3): 928-935. |
| 66 | SHI ET AL. (1999) "Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic." <i>Clinical Cancer Research</i> , 5:3711-3721. |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/511,465
Filing Date	October 14, 2004
First Named Inventor	Matthew H.T. Bui
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	306J-000220US
Date Submitted	March 29, 2005

- | | |
|----|--|
| 67 | SLAMON ET AL. (2001) "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2." <i>The New England Journal of Medicine</i> , 344(11):783-792. |
| 68 | SOBIN AND FLEMING (1997) "TNM Classification of Malignant Tumors, 5 Ed.." <u>Union Internationale Contre le Cancer and the American Joint Committee on Cancer</u> , <i>Cancer</i> (Phila.) 80: 1803-1804. |
| 69 | STEFFENS ET AL. (1997) "Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250," <i>Journal of Clinical Oncology</i> , 15(4): 1529-1537. |
| 70 | STEFFENS ET AL. (1999) "Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250." <i>Anticancer Research</i> , 19: 1197-1200. |
| 71 | STEFFENS ET AL. (1999) "Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250." <i>Clinical Cancer Research</i> , 5: 3268s-3274s. |
| 72 | STÖRKEL ET AL. (1997) "Classification of renal cell carcinoma: Workgroup No. 1." <u>Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)</u> <i>Cancer</i> , 80(5): 987-989. |
| 73 | TSO ET AL. (2001) "Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor." <i>Cancer Research</i> , 61:7925-7933. |
| 74 | TURNER ET AL. (1997) "MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker." <i>Human Pathology</i> , 28: 740-744. |
| 75 | UEMURA ET AL. (1994) "Vaccination with anti-idiotypic antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity." <i>International Journal of Cancer</i> , 58: 555-561. |
| 76 | UEMURA ET AL. (1997) "Expression of tumor-associated antigen MN/G250 in urologic carcinoma: potential therapeutic target." <i>The Journal of Urology</i> , 157(4)(Suppl): #1475. |
| 77 | UEMURA ET AL. (1999) "MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas." <i>British Journal of Cancer</i> , 81(4):741-746. |
| 78 | VAN DIJK ET AL. (1989) "Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen." <i>International Journal of Cancer</i> , 43: 344-349. |
| 79 | VISSERS ET AL. (1999) "The renal cell carcinoma associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes." <i>Cancer Research</i> , 59: 5554-5559. |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/511,465
	Filing Date	October 14, 2004
	First Named Inventor	Matthew H.T. Bui
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	306J-000220US
	Date Submitted	March 29, 2005

80	WYKOFF ET AL. (2000) "Hypoxia-inducible expression of tumor-associated carbonic anhydrases." <i>Cancer Research</i> , 60:7075-7083.	
81	WYKOFF ET AL. (2000) "Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling." <i>Oncogene</i> , 19: 6297-6305.	
82	ŽAVADA ET AL. (1993) "Expression of MaTu-MN protein in human tumor cultures and in clinical specimens." <i>International Journal of Cancer</i> , 54: 268-274.	
83	ZISMAN ET AL. (2001) "Improved prognostication of renal cell carcinoma using an integrated staging system." <i>Journal of Clinical Oncology</i> , 19(6):1649-1657.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.